Gland Pharma shares jump 7% to 52-week high; Nomura sees re-rating but Citi says 'sell'
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Gland Pharma shares jumped 7% to a 52-week high on Monday, November 9, following strong Q2FY27 results.
- ✓The company reported a 58.2% profit rise, driven by robust US market growth.
- ✓While Nomura sees a re-rating for the stock, Citi remains cautious and kept a 'sell' recommendation for the firm.
Story at a Glance
- Category
- Indian Markets
- Reported By
- cnbctv18
- Reading Speed
- 4 Minute(s)
- Market Focus
- India Economy
Nomura believes the company's strong Q2FY27 performance, particularly the continued momentum in the US market, supports its growth outlook. It also sees scope for an expansion in the stock's valuation multiple, reflecting a structural shift in Gland Pharma's business model towards a greater focus on CDMO operations.
Shares of Gland Pharma Ltd. were trading 7% higher on Monday, November 9, after the pharmaceutical company reported a strong set of September quarter (Q2FY27) results, supported by robust growth in its US business and improved operating performance.
Brokerages, however, remained divided on the stock's valuation and growth prospects, with Nomura maintaining a 'Buy' rating while Citi retained its 'Sell' recommendation.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
cnbctv18
Read the full, original unfiltered story directly on the publisher's portal.
This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.